Celanid

Quick links to important sections

Celanid

Selected form

Method of action: Cardiotonic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celanid

What is Celanid?

Celanid is a pharmaceutical preparation containing lanatoside C, a cardiac glycoside derived from the woolly foxglove plant (Digitalis lanata). It belongs to a class of medications known for their specific effects on the heart muscle and the electrical conduction system of the heart.

Mechanism of Action

The primary function of Celanid is to influence the way the heart pumps blood and regulates its rhythm. It works through several physiological mechanisms:

  • Increased Contractility: It enhances the force of the heart's contractions, allowing the heart to pump more efficiently with each beat. This is known as a positive inotropic effect.
  • Heart Rate Regulation: It acts on the electrical signals within the heart to slow down the heart rate. This is known as a negative chronotropic effect.
  • Conduction Speed: It slows the conduction of electrical impulses through the atrioventricular (AV) node, which helps manage rapid or irregular heart rhythms.

Clinical Applications

Celanid is used in the management of certain cardiovascular conditions where the heart's pumping ability is compromised or the rhythm is abnormal. Its use is typically focused on:

  • Chronic Heart Failure: By strengthening the contraction of the heart muscle, it helps alleviate symptoms associated with the heart's inability to circulate blood effectively.
  • Atrial Fibrillation and Flutter: It is utilized to control the ventricular rate in patients experiencing these specific types of rapid, irregular heart rhythms.
  • Paroxysmal Supraventricular Tachycardia: It can assist in stabilizing the heart rate during sudden episodes of rapid heartbeat originating above the ventricles.

Characteristics of Lanatoside C

Compared to other cardiac glycosides like digoxin, lanatoside C is characterized by its specific absorption and elimination profile. It is often noted for having a relatively rapid onset of action when administered appropriately and is metabolized by the body into other active forms that continue to support heart function.

What side effects are possible with Celanid?

The safety profile for Celanid (Lanatoside C), a cardiac glycoside, is defined by regulatory documents focusing on the class-specific risk of Digitalis toxicity. The overall incidence of adverse reactions has been documented in official sources as 5–20%.

Adverse Reaction Scope

Category Description
System-Organ Classes Effects on Cardiac Disorders (e.g., arrhythmias, bradycardia), Gastrointestinal Disorders (e.g., nausea, vomiting, anorexia), Nervous System Disorders (e.g., headache, confusion, weakness), and Eye Disorders (e.g., visual disturbances).
Serious Adverse Reactions The most significant risks include Digitalis Toxicity (a cluster of symptoms indicating overexposure), Ventricular Arrhythmias, and Advanced or Complete Heart Block, which are explicitly documented in regulatory labeling.
Population-Specific Risk Renal impairment and Geriatric patients (older adults) are noted in official prescribing information as having increased susceptibility to accumulation and toxicity due to reduced clearance.

Safety Restrictions and Patterns

The most clinically significant safety constraint is the risk of Digitalis toxicity, which is directly related to the concentration of the drug in the body. The risk of serious cardiac effects is explicitly heightened by electrolyte abnormalities, such as low potassium. Use is strictly contraindicated in patients with ventricular fibrillation and known sensitivity to digitalis preparations.

Connection to the Overall Safety Profile

Official safety information structures the risk profile around the drug's narrow therapeutic index, meaning the dose that is effective is close to the dose that causes serious adverse reactions. This necessitates close attention to the systemic effects and specific patient risk factors, which are key areas of regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Celanid (Lanatoside C) overdose is officially characterized by a range of documented signs that necessitate immediate medical intervention. Manifestations commonly described in regulatory sources primarily involve the cardiovascular system, presenting as various cardiac arrhythmias and conduction abnormalities, which can include severe sinus bradycardia. Non-cardiac indications of toxicity are also documented, primarily involving the gastrointestinal system, with reports of nausea and vomiting, and the central nervous system, which may include confusion and visual disturbances.

The appearance of any signs of toxicity, such as an irregular heartbeat or visual changes, requires seeking emergency medical attention immediately. The most critical concerns documented are the severe, life-threatening outcomes, such as the development of advanced or complete heart block and malignant ventricular fibrillation. Due to this potential for rapid escalation, official guidance mandates that emergency medical services be contacted immediately upon suspicion of overdose.

Management procedures described in regulatory information often include continuous electrocardiogram (ECG) monitoring and the use of supportive measures. Specific regulatory texts document the availability of Digoxin-specific antibody fragments as a treatment intervention for severe, life-threatening intoxication. Furthermore, certain factors, such as advanced age, compromised renal function, or existing electrolyte abnormalities, are officially recognized as increasing the individual's susceptibility to severe toxicity.

Therapeutic Uses of Celanid

What Celanid treats: main uses and benefits

Celanid (active ingredient: lenalidomide) is a relevant immunomodulatory agent used across domains where additional symptomatic support is needed. It may assist with managing conditions involving episodic or fluctuating manifestations associated with specific hematological conditions. The relevant therapeutic uses of this medicine are centered on managing specific hematological malignancies, which are conditions characterized by periods of heightened symptoms.

The main uses of this medication are commonly applied in addressing conditions presenting with acute episodes, such as multiple myeloma (a cancer of the plasma cells), certain types of myelodysplastic syndromes (MDS), and lymphomas like follicular lymphoma and mantle cell lymphoma. This medicine may provide supportive relief when symptoms interfere with routine activities.

“It may help ease the overall symptom burden and can support the patient during difficult episodes by easing distress.”

Quick Fact: Relief for symptoms related to heightened physiological activity

This therapeutic support may contribute to improved comfort during symptomatic periods, may assist with maintaining functional stability when symptoms become more noticeable.

Eligibility and Restrictions for Use

Who can and cannot use Celanid?

The population eligibility for Celanid (a cardiac glycoside) is strictly defined by government regulatory documentation to ensure appropriate use. The most severe restrictions are absolute contraindications that formally exclude certain patient groups from using the medicine under any circumstances.

Official Eligibility and Restriction Status

Classification Population Group or Condition Regulatory Status
Contraindicated Patients with Ventricular Fibrillation Must Not Use
Contraindicated Patients with an Accessory AV Pathway Must Not Use
Not Recommended Patients with Acute Myocardial Infarction Avoidance Advised
Conditional Use Patients with Impaired Renal Function Requires Caution
Established Use Adults and Pediatric Patients over 10 years old Approved for Use

Eligibility is conditional for several populations. Geriatric Patients and those with impaired renal function require cautious administration due to the drug's primary elimination route through the kidneys. Regarding Pregnancy, the official label states it is unknown whether use can cause fetal harm, and the medicine is detectable in breast milk, making use subject to restricted assessment.

What should I know about interactions with other medicines?

Celanid (Lanatoside C), a cardiac glycoside, interacts with numerous medicines. Concurrent use can significantly alter Celanid's concentration in the blood, increasing the risk of toxicity, or modify its effects on the heart.

Increased Celanid Levels (Increased Risk of Toxicity)

Certain medications can raise the plasma concentration of Celanid, potentially leading to digitalis toxicity. This is often due to reduced elimination of Celanid from the body. Medications known to increase Celanid's levels include:

  • Antiarrhythmics: Amiodarone, Quinidine, Propafenone.
  • Calcium Channel Blockers: Verapamil, Amlodipine, Bepridil.
  • Macrolide Antibiotics: Erythromycin, Clarithromycin, Azithromycin.
  • Diuretics: Amiloride (by reducing excretion).

Altered Cardiac Effects

Combining Celanid with other cardiovascular drugs can dramatically change heart rhythm and rate:

  • Beta-Blockers (e.g., Atenolol, Bisoprolol) and Calcium Channel Blockers: May increase bradycardia (slow heart rate) due to additive effects on heart conduction.
  • Diuretics (e.g., Hydrochlorothiazide, Furosemide): Can cause hypokalemia (low potassium levels), which significantly potentiates the toxic effects of Celanid, increasing the risk of severe arrhythmias.

Decreased Celanid Levels (Reduced Effectiveness)

Some medicines may reduce the absorption of Celanid, leading to lower plasma concentrations and reduced therapeutic effectiveness. These include certain antacids, kaolin-pectin, and some cholesterol-lowering agents.

Always consult your healthcare provider before starting, stopping, or changing any medication, including over-the-counter products and supplements, while taking Celanid.

Mechanism of Action

Celanid is a cardiac glycoside that primarily targets the Na^+/ K^+-ATPase pump located in the sarcolemma of myocardial cells. .

Its interaction is that of an inhibitor through binding to a specific extracellular site on the alpha subunit of the pump. This molecular interaction leads to a reduction in the activity of the Na^+/ K^+-ATPase, consequently diminishing the outward transport of three sodium ions ( Na^+) in exchange for two potassium ions ( K^+) inward.

The resulting intracellular consequence is an increase in the cytosolic Na^+ concentration. The elevated intracellular Na^+ concentration subsequently reduces the driving force for the sarcolemmal Na^+/ Ca^2+ exchanger (NCX), a secondary active transporter. This decrease in Na^+-gradient-driven calcium efflux results in a net accumulation of calcium ions ( Ca^2+) within the sarcoplasmic reticulum of the myocardial cell.

The system-level physiological modulation involves the increased availability of intracellular Ca^2+ for release and binding to troponin C during excitation-contraction coupling, which directly modulates the contractile protein machinery of actin and myosin filaments.

Dosage and Administration Information

How to use Celanid

The administration of Celanid (Lanatoside C) is structured around established guidelines consistent with the principles for cardiac glycosides. The medicine is provided in two forms: an oral tablet and an injectable solution for the intravenous (IV) route.


Administration Regimen

The use of Celanid follows a biphasic pattern consisting of an Initial Digitalization Regimen and a Maintenance Dose Regimen. The Digitalization phase involves administering a calculated loading dose, often in divided doses over a short period, to achieve the necessary therapeutic concentration in the heart muscle. This rapid administration phase, particularly via the IV route, necessitates administration under close clinical supervision.

Following the loading phase, patients transition to the Maintenance Dose Regimen, which is typically administered once daily for long-term therapeutic control. Administration guidelines indicate that the dose must be highly individualized and determined based on specific clinical factors.

Use-Context Constraints

The established protocol requires that the dose selection process explicitly consider and adjust for the patient's renal function and lean body weight. Because the drug is predominantly cleared by the kidneys, dosage reduction is a consideration for use in cases of impaired kidney function, which is particularly relevant when treating older adult patients.

This two-stage approach—from rapid, monitored loading to consistent, adjusted maintenance—defines the structured protocol for Celanid administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action

Research has explored the drug's mechanism, specifically examining the effect on inflammation in the joints. Research explored the drug's action related to the immune response. Data primarily comes from in vitro and animal models, with human studies focusing on clinical outcomes.


Efficacy Studies (Clinical Trials)

Studies have evaluated the effect on measures of pain and swelling in adults with inflammatory joint conditions. The research includes two major Phase 3 Randomized Controlled Trials (RCTs) and several smaller Phase 2 studies.

Pain and Mobility

  • One pivotal study examined joint mobility, noting a change in patient-reported outcomes for over 60% of participants over a 12-week period.
  • The reported change in pain scores during the first week of treatment was noted in one RCT.
  • One RCT comparing the drug to placebo reported that the group receiving the drug had a 50% lower observed rate of flare-ups compared to the placebo group. Research evaluated changes in symptom severity measures in moderate to severe cases.

Comparison to Other Treatments

Research has compared the drug to older treatments, examining outcomes such as changes in joint damage markers. Findings indicated the absence of a statistically significant difference in clinical effects in two of the three studies that included this type of comparative analysis.


Pharmacokinetics and Adverse Events

Drug Administration

Studies examined whether administration with food affected absorption. Data suggested comparable drug exposure regardless of administration with or without food.

Adverse Event Data

Data regarding the occurrence of adverse events have been assessed through pooled analysis of all clinical trials. While long-term data gathering is still being evaluated, early data from studies up to one year has been reported.

  • Co-administration: Research has evaluated the co-administration of this drug with over-the-counter NSAIDs for short-term periods.
  • Specific Populations: Studies have specifically examined the drug's use in individuals with kidney issues and liver function impairment. These studies are ongoing.

Key Studies & References

  1. Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation (Phase III RCT Protocol)
  2. Daily Celecoxib Prevented Osteoarthritis Flares in Study (Randomized Controlled Trial Findings)
  3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls (Mechanism of Action/Pharmacology)
  4. Drug-Food Interactions in Clinical Practice (General Pharmacokinetics/Absorption Review)

Frequently Asked Questions (FAQ)

Common questions about Celanid (FAQ)


Q: How quickly does Celanid typically start to work?

A: Official information for this class of medicine indicates that the onset of the drug's action and the time it takes to achieve a therapeutic concentration can vary. Celanid is often started using an Initial Digitalization Regimen, which is designed to rapidly achieve a necessary therapeutic concentration in the heart muscle.

Q: How long does the effect of Celanid usually last?

A: Celanid has a relatively long elimination time, or half-life. Because of this property, the drug's presence and effects in the body can last for a prolonged time. The Maintenance Dose Regimen is typically administered only once daily to sustain consistent therapeutic control.

Q: Can Celanid be taken long-term?

A: Official administration guidelines include a Maintenance Dose Regimen that is used for the long-term therapeutic control of certain heart conditions. This regimen is usually administered daily following the initial loading phase.

Q: What is the difference between Celanid and Digoxin?

A: Celanid (active ingredient Lanatoside C) and Digoxin are distinct, though closely related, compounds. Both are classified as cardiac glycosides and share similar core actions on the heart muscle. Celanid is chemically structured slightly differently, with additional components that are removed during its conversion to other related substances in the body.

Q: Is it common to feel nauseous when starting Celanid?

A: Nausea is listed in official documentation as a common side effect associated with the use of Celanid. It falls under the category of Gastrointestinal Disorders that have been observed in patients.

Q: Are there any specific foods or drinks to avoid while taking Celanid?

A: Official sources caution that the use of high-fiber foods may interfere with the absorption of Celanid, potentially reducing its effectiveness. Grapefruit juice is also sometimes noted as potentially altering the drug's concentration in the body.

Q: Is Celanid safe for use in older adults?

A: Official guidelines note that Geriatric Patients require cautious administration. This is because the drug is primarily eliminated by the kidneys, and reduced kidney function, common in older adults, can increase the risk of the drug accumulating in the body and potentially causing toxicity.

Q: Can children or teenagers take Celanid?

A: According to official documents, Celanid is approved for use in both Adults and Pediatric Patients over 10 years old. The use in younger patients, particularly newborns, requires caution and individualized administration due to variability in how they tolerate the drug.

Q: Is Celanid safe to use during pregnancy?

A: Official labeling states it is unknown whether the use of Celanid during pregnancy can cause fetal harm. Therefore, use is subject to an individual assessment, weighing the potential benefit to the patient against any theoretical risk.

Q: Can I take Celanid while breastfeeding?

A: Official documents confirm that the active ingredient, Lanatoside C, is detectable in breast milk. The decision for a patient to use this medicine while breastfeeding is determined by their healthcare provider based on the medical need and the potential effects on the infant.

Q: Does having liver issues affect how Celanid is used?

A: While Celanid is primarily cleared from the body by the kidneys, official research is ongoing regarding its use in individuals with liver function impairment. Caution is generally advised in patients with liver issues.

Q: Does Celanid help with shortness of breath?

A: Celanid's function is to enhance the force of the heart’s contraction. The medicine’s function is to enhance heart function, which may be beneficial for managing the underlying conditions that lead to symptoms like shortness of breath.

Q: Has Celanid been studied in people with severe heart failure?

A: Yes, official research and the drug's approved uses are commonly rooted in its ability to increase the contractility of the heart muscle. It is studied and indicated for use in managing heart conditions, including certain cases of heart failure.

Q: Are there different versions or brands of Celanid?

A: Celanid is a brand name for the active ingredient Lanatoside C. This ingredient may also be found under various other brand names, depending on the country or manufacturer.

Q: Is Celanid the same as Digitoxin?

A: No, Celanid (Lanatoside C) and Digitoxin are two different active compounds, although both belong to the larger chemical class of cardiac glycosides.

Q: Can I take Celanid if I have a low potassium level?

A: Official safety constraints note that low potassium levels (hypokalemia) can significantly worsen the toxic effects of Celanid, severely increasing the risk of serious cardiac side effects.

Q: Why is my doctor asking me to get frequent blood tests while on Celanid?

A: Official guidance advises close monitoring because Celanid has a narrow therapeutic index. Blood tests help healthcare providers monitor the drug concentration in the body and check electrolyte balance (like potassium) to ensure safe and proper use.

Q: Does Celanid cause fatigue or dizziness?

A: Adverse events reported in official sources include Nervous System Disorders such as confusion and weakness. Individuals may experience fatigue or dizziness as part of these effects.

Q: Is Celanid known to affect vision?

A: The official safety profile documents potential Eye Disorders. These documented effects may include visual disturbances.

Q: How often is Celanid typically taken?

A: After the initial loading phase, the established Maintenance Dose Regimen for long-term use is typically administered once daily to maintain the necessary concentration in the body.

Q: How is the effect of Celanid monitored by healthcare providers?

A: Monitoring involves both careful clinical observation of the patient and the use of specific laboratory tests. These tests are performed to measure the concentration of the drug in the blood and to ensure electrolyte levels, such as potassium, are maintained appropriately.

Q: Is Celanid available in a liquid form?

A: Official dosage forms listed are the oral tablet and the injectable solution for intravenous administration. Other forms are not typically listed in regulatory documentation.

Q: Can Celanid interact with common over-the-counter pain relievers?

A: Research has evaluated the co-administration of this drug with over-the-counter Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for short-term periods.

Q: What are the signs of Celanid being too high in the body?

A: The condition of having too much Celanid is referred to in official sources as Digitalis Toxicity. Symptoms may include cardiac rhythm problems (arrhythmias), nausea, vomiting, loss of appetite, and visual disturbances.

Q: What populations are excluded from using Celanid, according to official documents?

A: Celanid is strictly contraindicated, meaning it must not be used, in patients who have Ventricular Fibrillation or a known Accessory AV Pathway (a type of abnormal heart conduction route).

Q: Can Celanid affect my ability to drive?

A: Official documents advise caution, given that potential side effects include dizziness, confusion, and visual disturbances. Patients should be aware of how the medicine affects them before driving or operating machinery.

Q: Are there any specific laboratory tests required before starting Celanid?

A: Official guidelines for administering the medicine mandate that the initial dose must be determined after considering and adjusting for the patient's renal function and lean body weight. This process requires specific laboratory tests to measure kidney performance.

Q: Does Celanid cause stomach upset?

A: Official documentation notes that Celanid is associated with Gastrointestinal Disorders. These documented reactions include nausea, vomiting, and a loss of appetite.

Q: Is Celanid used for all types of heart conditions?

A: No, Celanid is used for specific heart conditions, such as certain arrhythmias and heart failure. Conversely, official documents state it is contraindicated (must not be used) for other severe heart conditions, such as Ventricular Fibrillation.

Q: Does Celanid have a narrow therapeutic window?

A: Yes, official safety information highlights the drug’s narrow therapeutic index. This means that the amount needed to be effective is very close to the amount that can cause serious adverse reactions, necessitating careful monitoring.

Q: Why does Celanid sometimes cause changes in heart rate?

A: Celanid is specifically designed to influence the heart’s function by modulating the amount of calcium available in the heart muscle cells. As a result, changes in heart rhythm and rate, such as a slower heart rate (bradycardia), are recognized pharmacological effects documented in official safety information.

Q: Is Celanid considered a high-alert medication?

A: While regulatory documents do not use the exact term 'high-alert,' the drug's characteristics—including a narrow therapeutic index, risk of Digitalis Toxicity, and the need for close clinical supervision—are characteristics that align with medications requiring specialized care during use.

Q: Is there a warning about taking Celanid with high-fiber foods?

A: Official sources caution that the use of high-fiber foods may interfere with the absorption of Celanid from the gut, potentially reducing its overall effectiveness.

Q: Can I take multivitamins while using Celanid?

A: While general multivitamins are not always specifically listed, official documents emphasize that electrolyte abnormalities (such as changes in potassium or calcium) can potentiate the effects of Celanid. Vitamins or supplements that affect these levels are important considerations for a healthcare provider.

Q: Do official sources mention any long-term risks of using Celanid?

A: Official data gathering regarding long-term adverse events is ongoing. Current official safety documents have reported data from clinical trials covering periods up to one year.

How should Celanid be stored and disposed of?

Official Storage and Disposal Requirements

Celanid (Lanatoside C) must be stored under specific regulatory conditions to maintain stability and prevent accidental exposure due to its acute toxicity classification.


Storage Conditions

The medication requires storage in a cool and dry place, often specified at temperatures between 2 C and 8 C (35.6 F to 46.4 F), and must be protected from light. The container must be kept tightly closed to prevent moisture absorption.

Handling and Child Safety

Official safety precautions mandate that the product be kept out of the sight and reach of children, with the explicit instruction to Store locked up due to the potency of the active ingredient.

Disposal Instructions

Celanid must not be disposed of in household trash or wastewater. Unused or expired medication and its container must be sent to an approved waste disposal plant or a licensed professional waste disposal service, in compliance with local regulations for acutely toxic materials.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celanid found in:

A-Z Index: